Triple combination treatment of chronic hepatitis C
Authors:
P. Husa
Authors place of work:
Klinika infekčních chorob Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Petr Husa, CSc.
Published in the journal:
Vnitř Lék 2012; 58(7 a 8): 202-204
Category:
60th Birthday prof. MUDr. Miroslav Souček, CSc.
Summary
The 2011 has brought about a significant change in the treatment of chronic hepatitis C virus (HCV) infection. This change has been enabled by commercial availability of new antiviral agents for treatment of chronic HCV infection – telaprevir and boceprevir – in combination with pegylated interferon (PEG-IFN) α and ribavirin (RBV). The triple combination is significantly more effective than the PEG-IFN and RBV combination alone in antiviral treatment-naive patients as well as in patients in whom the traditional PEG-IFN and RBV combination did not provide permanent HCV infection elimination. In treatment-naive patients, the triple combination is approximately 2-fold more effective than the standard treatment with PEG-IFN and RBV and the effect of the triple combination is 3-fold higher when used in pre-treated patients instead of repeated PEG-IFN and RBV treatment.
Key words:
chronic hepatitis C – boceprevir – telaprevir
Zdroje
1. Urbánek P. Infekce virem hepatitidy C. Praha: Galén 2004.
2. Husa P. Virové hepatitidy. Praha: Galén 2005.
3. Urbánek P, Husa P, Galský J et al. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). Doporučený postup České hepatologické společnosti a Společnosti infekčního lékařství ČLS JEP. In press 2012.
4. Poordad F, McCone J Jr, Bacon BR et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195–1206.
5. Bacon BR, Gordon SC, Lawitz E et al. HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207–1217.
6. Jacobson IM, McHutchinson JG, Dusheiko G et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405–2416.
7. Sherman KE, Flamm SL, Afdhal NH et al. Telaprevir in combination with peginterferon alfa 2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid virological response: final results of Phase 3 ILLUMINATE study. Hepatology 2010; 52: 401A.
8. Zeuzem S, Andreone P, Pol S et al. REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417–2428.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2012 Číslo 7 a 8
Najčítanejšie v tomto čísle
- Myocardial infarction the young – our results and experience
- An anaesthesiologist’s perspective on requirements for pre-surgery examinations
- Megakaryopoesis and platelet genesis
- Aldosterone antagonists in chronic heart failure treatment